Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAST: IMT Prior to Allogeneic Stem Cell Transplant
NCT06355583Phase 2Recruiting
- Sponsor
- Imperial College London
- Start
- May 2024
- Primary completion
- Feb 2026
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of EBX-102 in graft-versus-host disease (GVHD), Infection, sponsored by Imperial College London. Started May 2024; status: recruiting.
02
Drugs
EBX-102
03
Conditions
graft-versus-host disease (GVHD)Infection
Beyond the preview
Go deeper on NCT06355583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06355583.